^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:ofranergene obadenovec (VB-111) (Angiogenesis inhibitor, Vascular disrupting agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    VBL Press Release
    Title:

    VBL Therapeutics Receives FDA Fast Track Designation for Lead Compound VB-111

    Published date:
    11/27/2013
    Excerpt:
    VBL Therapeutics...announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology drug VB-111, for prolongation of survival in patients with Recurrent Glioblastoma Multiforme (rGBM).